Germline analysis from tumor-germline sequencing dyads to identify clinically actionable secondary findings

Clinical Cancer Research

Volumn 22, Issue 16, 2016, Pages 4087-4094

  Seifert, Bryce A ^a,b   O'Daniel, Julianne M ^a,b   Amin, Krunal ^a   Marchuk, Daniel S ^a   Patel, Nirali M ^a,b   Parker, Joel S ^a,b   Hoyle, Alan P ^b   Mose, Lisle E ^b   Marron, Andrew ^b   Hayward, Michele C ^b   Bizon, Christopher ^b   Wilhelmsen, Kirk C ^a,b   Evans, James P ^a,b   Earp, H Shelton ^b   Sharpless, Norman E ^a,b   Hayes, D Neil ^b   Berg, Jonathan S ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CHECKPOINT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 2A; TUMOR MARKER;

ADULT; AGED; ARTICLE; ATM GENE; CANCER SUSCEPTIBILITY; CDKN2A GENE; CHEK2 GENE; EXPLORATORY RESEARCH; FAMILIAL CANCER; FEMALE; FRAMESHIFT MUTATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GERMLINE MUTATION; HUMAN; INDEL MUTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MISSENSE MUTATION; NEXT GENERATION SEQUENCING; NONSENSE MUTATION; PRIORITY JOURNAL; TUMOR GERMLINE SEQUENCING; TUMOR SUPPRESSOR GENE; GENETIC SCREENING; GENETICS; GENOMICS; HEREDITARY TUMOR SYNDROME; HIGH THROUGHPUT SEQUENCING; MORTALITY; NEOPLASM; PROCEDURES; PROGNOSIS;

BIOMARKERS, TUMOR; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOMICS; GERM-LINE MUTATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; NEOPLASMS; NEOPLASTIC SYNDROMES, HEREDITARY; PROGNOSIS;

EID: 84982108431     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-0015     Document Type: Article

References (49)

1. Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 2014;158:929-44.
2. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu Y-M, Cao X, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 2011;3:111ra121.
3. Jones S, Anagnostou V, Lytle K, Parpart-Li S, Nesselbush M, Riley DR, et al. Personalized genomic analyses for cancer mutation discovery and interpretation. Sci Transl Med 2015;7:283ra53-283ra53.
4. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 2010;11:685-96.
5. Jeck WR, Parker J, Carson CC, Shields JM, Sambade MJ, Peters EC, et al. Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma. Pigment Cell Melanoma Res 2014;27:653-63.
6. Schlussel AT, Gagliano RA, Seto-Donlon S, Eggerding F, Donlon T, Berenberg J, et al. The evolution of colorectal cancer genetics-Part 1: from discovery to practice. J Gastrointest Oncol 2014;5:326-35.
7. Zhang S, Royer R, Li S, McLaughlin JR, Rosen B, Risch HA, et al. Frequencies of BRCA1 and BRCA2 mutations among 1, 342 unselected patients with invasive ovarian cancer. Gynecol Oncol 2011;121:353-7.
8. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, et al. BRCA1 and BRCA2mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005;104:2807-16.
9. Bombard Y, Robson M, Offit K. Revealing the incidentalome when targeting the tumor genome. JAMA 2013;310:795-6.
10. Schrader KA, Cheng DT, Joseph V, Prasad M, Walsh M, Zehir A, et al. Germline variants in targeted tumor sequencing using matched normal DNA. JAMA Oncol 2016;2:104-11.
11. Meric-Bernstam F, Brusco L, Daniels M, Wathoo C, Bailey A, Strong L, et al. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Ann Oncol 2016;27:795-800.
12. Zhao X, Wang A, Walter V, Patel NM, Eberhard DA, Hayward MC, et al. Combined targeted DNA sequencing in non-small cell lung cancer (NSCLC) using UNCseq and NGScopy, and RNA sequencing using UNCqeR for the detection of genetic aberrations in NSCLC. PLoS ONE 2015;10:e0129280.
13. Garrison E, Marth G. Haplotype-based variant detection from short-read sequencing. arXiv [Internet]; 2012 [cited 2015 Jul. 22]. Available from: http://arxiv.org/pdf/1207.3907.pdf.
14. TR-14-02 The GMW, A genetic medical workflow engine | RENCI [Internet]; 2015 [cited 2015 Jul. 3]. Available from: http://renci.org/technicalreports/tr-14-02-the-gmw-a-genetic-medical-workflow-engine/.
15. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med 2015;17:405-23.
16. Mose LE, Wilkerson MD, Hayes DN, Perou CM, Parker JS. ABRA: improved coding indel detection via assembly-based realignment. Bioinformatics 2014;30:2813-5.
17. Economopoulou P, Dimitriadis G, Psyrri A. Beyond BRCA: New hereditary breast cancer susceptibility genes. Cancer Treat Rev 2015;41:1-8.
18. Raczy C, Petrovski R, Saunders CT, Chorny I, Kruglyak S, Margulies EH, et al. Isaac: ultra-fast whole-genome secondary analysis on Illumina sequencing platforms. Bioinformatics 2013;29:2041-3.
19. ®) [Internet]. Seattle, WA: University of Washington; 1993. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1201/.
20. Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA 2011;108:18032-7.
21. ®) [Internet]. Seattle, WA: University of Washington; 1993. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1109/.
22. ®) [Internet]. Seattle, WA: University of Washington; 1993. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1220/.
23. Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 1999;23:166-75.
24. Ghiorzo P. Genetic predisposition to pancreatic cancer. World J Gastroenterol 2014;20:10778-89.
25. Matloff E. Cancer principles and practice of oncology: handbook of clinical cancer genetics. Philadelphia, PA: Lippincott Williams & Wilkins; 2013.
26. Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL. A practice guideline from the American college of medical genetics and genomics and the national society of genetic counselors: referral indications for cancer predisposition assessment. Genet Med 2015;17:70-87.
27. La Duca H, Stuenkel AJ, Dolinsky JS, Keiles S, Tandy S, Pesaran T, et al. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2, 000 patients. Genet Med 2014;16:830-7.
28. Minion LE, Dolinsky JS, Chase DM, Dunlop CL, Chao EC, Monk BJ. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2. Gynecol Oncol 2015;137:86-92.
29. Phelan CM, Iqbal J, Lynch HT, Lubinski J, Gronwald J, Moller P, et al. Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study. Br J Cancer 2014;110:530-4.
30. Schneider J, Illig T, Rosenberger A, Bickeböller H, Wichmann H-E. Detection of ATM gene mutations in young lung cancer patients: a populationbased control study. Arch Med Res 2008;39:226-31.
31. Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013;15:565-74.
32. Parsons DW, Roy A, Plon SE, Roychowdhury S, Chinnaiyan AM. Clinical tumor sequencing: an incidental casualty of the American College of Medical Genetics and Genomics recommendations for reporting of incidental findings. J Clin Oncol 2014;32:2203-5.
33. Rahman N. Realizing the promise of cancer predisposition genes. Nature 2014;505:302-8.
34. O'Daniel JM, Lee K. Whole-genome and whole-exome sequencing in hereditary cancer: impact on genetic testing and counseling. Cancer J 2012;18:287-92.
35. Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 2008;29:1282-91.
36. Rehm HL, Berg JS, Brooks LD, Bustamante CD, Evans JP, Landrum MJ, et al. ClinGen - the clinical genome resource. N Eng J Med 2015;372:2235-42.
37. Kurian AW, Hare EE, Mills MA, Kingham KE, McPherson L, Whittemore AS, et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol 2014;32:2001-9.
38. Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triplenegative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol 2015;33:304-11.
39. La Duca H, Stuenkel AJ, Dolinsky JS, Keiles S, Tandy S, Pesaran T, et al. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2, 000 patients. Genet Med 2014;16:830-7.
40. Presidential Commission for the Study of Bioethical Issues. Anticipate and Communicate: ethical management of incidental and secondary findings in the clinical, research, and direct-to-consumer contexts [Internet]; 2015 [cited 2015 Jul. 3]. Available from: http://bioethics.gov/node/3183.
41. Tripathy D, Harnden K, Blackwell K, Robson M. Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic? BMC Med 2014;12:140.
42. Mai PL, Vadaparampil ST, Breen N, McNeel TS, Wideroff L, Graubard BI. Awareness of cancer susceptibility genetic testing: the 2000, 2005, and 2010 National Health Interview Surveys. Am J Prev Med 2014;46:440-8.
43. Van Riel E, Van Dulmen S, Ausems MGEM. Who is being referred to cancer genetic counseling? Characteristics of counselees and their referral. J Community Genet 2012;3:265-74.
44. Overbeek LIH, Hoogerbrugge N, Van Krieken JHJM, Nagengast FM, Ruers TJM, Ligtenberg MJL, et al. Most patients with colorectal tumors at young age do not visit a cancer genetics clinic. Dis Colon Rectum 2008;51:1249-54.
45. McCarthy AM, Bristol M, Fredricks T, Wilkins L, Roelfsema I, Liao K, et al. Are physician recommendations for BRCA1/2 testing in patients with breast cancer appropriate? A population-based study. Cancer 2013;119:3596-603.
46. Karageorgos I, Mizzi C, Giannopoulou E, Pavlidis C, Peters BA, Zagoriti Z, et al. Identification of cancer predisposition variants in apparently healthy individuals using a next-generation sequencing-based family genomics approach. Hum Genomics 2015;9:12.
47. Amendola LM, Dorschner MO, Robertson PD, Salama JS, Hart R, Shirts BH, et al. Actionable exomic incidental findings in 6503 participants: challenges of variant classification. Genome Res 2015;25:305-15.
48. Raymond VM, Gray SW, Roychowdhury S, Joffe S, Chinnaiyan AM, Parsons DW, et al. Germline findings in tumor-only sequencing: points to consider for clinicians and laboratories. J Natl Cancer Inst 2016;108.
49. Evans DG, Birch JM, Narod SA. Is CHEK2 a cause of the Li-Fraumeni syndrome? J Med Genet 2008;45:63-4.